Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(7): e41482.
Published online 2012 July 25. doi:  10.1371/journal.pone.0041482
PMCID: PMC3405092

Dopamine Genes (DRD2/ANKK1-TaqA1 and DRD4-7R) and Executive Function: Their Interaction with Obesity

Antonio Verdejo García, Editor


Obesity is a multifactorial disease caused by the interaction between genotype and environment, and it is considered to be a type of addictive alteration. The A1 allele of the DRD2/ANKK1-TaqIA gene has been associated with addictive disorders, with obesity and with the performance in executive functions. The 7 repeat allele of the DRD4 gene has likewise been associated with the performance in executive functions, as well as with addictive behaviors and impulsivity. Participants were included in the obesity group (N = 42) if their body mass index (BMI) was equal to or above 30, and in the lean group (N = 42) if their BMI was below 25. The DRD2/ANKK1-TaqIA and DRD4 VNTR polymorphisms were obtained. All subjects underwent neuropsychological assessment. Eating behavior traits were evaluated. The ‘DRD2/ANKK1-TaqIA A1-allele status’ had a significant effect on almost all the executive variables, but no significant ‘DRD4 7R-allele status’ effects were observed for any of the executive variables analyzed. There was a significant ‘group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on LN and ‘group’ x ‘DRD4 7R-allele status’ interaction effect on TMT B-A score. Being obese and a carrier of the A1 allele of DRD2/ANKK1-TaqIA or the 7R allele of DRD4 VNTR polymorphisms could confer a weakness as regards the performance of executive functions.


Obesity is a chronic multifactorial disease caused by the interaction between genotype and environment, and it is considered the second cause of premature and avoidable mortality, after tobacco [1], [2]. It has also been suggested as a possible risk factor for neurodegenerative diseases [3], [4] and has been associated with an increased rate of psychiatric disease, such as depression [5]. At the same time, obesity can be considered as a type of addictive disorder involving an alteration of normal cerebral functioning, one that is characterized by compulsive food intake and an inability to limit ingestion [6]. Both palatable food and drugs appear to activate the same mesolimbic dopamine reward system in the human brain and animal models [7][9]. Thus, dopamine genes may influence the relationship between obesity, the sensitivity to reinforcement and decision making.

DRD2 is a gene encoding the D2 dopamine receptor, which is mainly expressed in the striatum [10][13]. The DRD2/ANKK1-TaqIA polymorphism is located, 10 kb downstream from the DRD2 gene, in the exon 8 of the adjacent gene, denoted the ankyrin repeat and kinase domain containing 1 (ANKK1) [14]. The DRD2/ANKK1-TaqIA polymorphism modulates the density of D2 receptors. Carriers of the A1 allele have shown up to 30% reduced D2 receptor density compared to homozygous A2 allele carriers [11], [13], [15], [16]. This reduction is particularly prominent in ventral parts of the caudate and putamen. Reduced glucose metabolism is also observed in carriers of the A1 allele, not only in the striatum but also in remote areas such as the ventral and medial prefrontal cortex [17].

The A1 allele of the DRD2/ANKK1-TaqIA gene has been associated with both addictive disorders [18][20] and obesity [21], [22]. The A1 allelic prevalence has been reported to be significantly higher in obese individuals than in lean controls [23][25]. Moreover, obese subjects, relative to lean ones, have fewer D2 receptors in the striatum [22], [26], [27].

Further to these findings, imaging studies have reported that the reductions in D2 receptors are associated with decreased metabolism in prefrontal cortical regions in obese subjects [28], in whom an inverse relationship between body mass index (BMI) and D2 receptors has also been described; specifically, those individuals with the lowest D2 values had the largest BMI [22]. Lower prefrontal metabolic activity has also been reported in healthy adults with the highest BMI [28], [29].

There are controversial results regarding the relationship between DRD2/ANKK1-TaqIA polymorphisms and cognitive processes. Berman and Noble [30] reported significantly reduced visuo-spatial performance in healthy children with the A1 allele compared with A1 non-carriers. An association between possession of the A1 allele of the DRD2/ANKK1-TaqIA polymorphism and intelligence has also been reported, but in the opposite direction. Carriers of the A1/A1 genotype in an adult female sample had a significantly higher IQ than did carriers of the A2/A2 genotype [31]. In a sample of memory-impaired subjects, those homozygous for the A2 allele exhibited worse performance in verbal memory and general cognitive ability than did those subjects bearing the A1 allele [32].

As regards frontal functions some studies in healthy adult samples have found that carriers of the A1 allele (who have a lower density of D2 receptors) display better behavioural flexibility than do A1 non-carriers [33], [34]. Other authors have reported that A1 carriers have difficulty in learning from negative feedback in a reinforcement learning task [35] and are less efficient at learning to avoid actions that have negative consequences [36], although some investigators have failed to find an association between frontal function and the DRD2/ANKK1-TaqIA polymorphism [37].

Another gene encoding dopamine receptors is DRD4, which is highly expressed in the prefrontal cortex and other brain regions that are involved in the reward circuits that mediate the reinforcing properties of food, such as the hippocampus, amygdala and hypothalamus [38], [39]. The most widely studied polymorphism of the DRD4 gene is located in the third exon and contains a 48 base-pair, variable number of tandem repeats (48-bp VNTR). Nine alleles of the DRD4 48-bp VNTR have been identified worldwide, with the number of repeats ranging between 2 and 10. The 4- and 7-repeat (7R and 4R) alleles are the most common globally [40]. The number of 48-bp repeats has been hypothesized to affect the transmitted signal in the postsynaptic neuron. Individuals with at least one allele containing seven or more repeats show both reduced binding affinities and receptor densities for dopamine neurotransmission [41].

The DRD4 gene has been associated with addictive behaviours [42] and with increased food intake in patients treated with D4 receptor-related antipsychotics [43]. The 7R allele has been linked to attention deficit and hyperactivity disorder (ADHD) [44][46] and to body weight gain in patients with seasonal affective disorder [47]. The 7R allele has also been found to be associated with impulsivity and lower levels of response inhibition in healthy adults, both alone and in combination with other polymorphisms in dopamine system genes, such as DRD2 [48], [49].

Research into the link between DRD4 and cognitive functions has also yielded mixed results. Some studies have reported associations between being a carrier of 7R allele and impairment on executive function tasks in healthy children [50], as well as in children with ADHD [50][52]. However, Manor et al. [53] reported just the opposite: their ADHD children with the DRD4 long repeats (6–8) performed better on attention than did those bearing the DRD4 short repeats (2–5). In a recent study of healthy adults, 7R allele carriers showed impaired reaction times compared with non-carriers [54]. In addition, a recent experimental study demonstrated impaired attentional performance in animals with a genetically-induced reduction in DRD4 expression [55]. Other studies, however, have shown no differences in performance on different attentional domains for 7R carriers among ADHD patients [44], [51], [53], .

Since the DRD2 and DRD4 genes have been associated with susceptibility to obesity and anomalous eating behaviour, and given that polymorphisms of these genes seem to affect the performance of executive functions, which appear to be altered in obesity, it would seem logical to ask whether there is any relationship between these polymorphisms and executive function in obese subjects. No study to date has examined a possible effect of DRD2/ANKK1-TaqIA and DRD4 VNTR polymorphisms on executive performance in the obese population. However, it must be taken into account that depression is the most frequent co-morbidity of obesity [5] and is also associated with alteration of executive functions [57]. What is more, depression has been shown to be a mediator between executive function and obesity [58], and striatal dopamine levels are low in depressive subjects [59]. For these reasons we should consider the levels of depression as a control variable in the analysis of any relationship between these polymorphisms and executive function in obese subjects.

Thus, the purpose of the present study was to assess the association between two dopamine genes and executive function and their potential interactions with obesity. The relationship between these polymorphisms and eating behaviour variables was also studied.

Materials and Methods

Participants were randomly selected from a population base of 1539 people living within the catchment area of three public medical centres belonging to the Consorci Sanitari de Terrassa. The recruitment process continued until two samples with similar demographic features were obtained. Specifically, 816 potential participants were contacted by telephone (see the Figure S1 for detailed information on data inclusion) and 126 agreed to participate in the study; of these, 16 individuals were excluded (see criteria below) and 26 subsequently decided to leave the study. The final sample therefore comprised 84 people, with an age range of 19 to 40 years. Participants were included in the obesity group (N = 42) if their body mass index (BMI) was equal to or above 30, and in the lean group (N = 42) if their BMI was below 25. Exclusion criteria were: a history of neurological or psychiatric disorder, with the possible presence of anxiety or depression being assessed via the Hospital Anxiety and Depression Scale (HADS) [60], and the pathological use of alcohol and/or drugs being evaluated with the Structured Clinical Interview for DSM-IV (SCID-I) [61]; a history of any disorder that could be related to obesity (e.g. thyroid dysfunctions); the presence of diabetes or hypertension; BMI in the overweight range (i.e. 25–29.9); and the presence of cognitive impairment. The study was approved by the institutional ethics committee (Comissió de Bioètica de la Universitat de Barcelona (CBUB); Institutional Review Board IRB 00003099 Assurance number: FWA00004225; and the research was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from each participant prior to taking part in the study. The demographic and clinical characteristics of the obese and control groups are shown in table 1 and table 2.

Table 1
Demographic and clinic characteristics in obese subjects.
Table 2
Demographic and clinic characteristics in normal-weight subjects.


Venous blood was drawn from all subjects and genomic DNA was extracted automatically by the MagNaPure Compact Instrument (Roche Applied Science, Barcelona, Spain) according to the manufacturer’s protocol. The DRD2/ANKK1 TaqIA (rs1800497) and DRD4 VNTR (rs1805186) polymorphisms were analysed as described below.

The DRD2/ANKK1-TaqIA polymorphism was amplified by polymerase chain reaction (PCR) containing 100 ng of genomic DNA from each subject, 0.5 µM each of forward (5′-GGCTGGCCAAGTTGTCTA-3′) and reverse (5′-CCTTCCTGAGTGTCATCA-3′) primers, 1× PCR buffer, 1 mM MgCl2, 200 µM of dNTPs and 2.5 units of BioTaq DNA polymerase (Bioline, Ecogen, Barcelona, Spain). The PCR programme was 95°C for 5 min followed by 35 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 1 min. The 302 bp PCR product was digested with TaqαI enzyme (New England Biolabs, Izasa, Barcelona, Spain) for 90 min at 65°C and visualized under ultraviolet light on an 8% ethidium bromide acrylamide gel. The DRD2-A2 allele was cleaved into two fragments of 176 and 126 bp, whereas the DRD2-A1 allele was not cleaved.

The DRD4 48-bp VNTR polymorphism was amplified by PCR containing 100 ng genomic DNA, 0.5 µM of each primer (5′-GCGACTACGTGGTCTACTCG-3′ as forward and 5′-AGGACCCTCATGGCCTTG-3′ as reverse), 1× PCR buffer, 1 mM MgCl2, 5% DMSO, 200 µM of dATP, dCTP and dTTP, 140 µM of dGTP, 60 µM of 7-deazaGTP and 2.5 units of BioTaq DNA polymerase (Bioline). Cycling conditions were 35 cycles at 94°C for 30 s, 63°C for 30 s and 72°C for 1 min. Amplification products were resolved by 5% acrylamide gel electrophoresis and were subsequently stained with ethidium bromide and visualized under ultraviolet light. Fragment sizes were determined by comparison with molecular length standards. A 4-repeat PCR product has a length of 475 bp. Genotyping was successful in all participants. Each genotype was recoded as carrier versus non-carrier of the allele of interest.

Neuropsychological Assessment

All subjects underwent neuropsychological assessment of executive functions, this being based on the following tests. Letter-Number Sequencing (LN) was used to assess processing speed and verbal and visuo-spatial working memory (WM) [62], [63]. Visual scanning, tracking and motor speed were assessed by the written part of Symbol Digit Modalities Test (SDMT) [64]. Parts A and B of the Trail Making Test (TMT) were administered to measure visual scanning, motor speed and attention and mental flexibility [65]; a difference score (B-A) that removes the speed element from the test evaluation was calculated here [66]. The Controlled Oral Word Association Test (COWAT) was used to evaluate verbal fluency [67]. This measure has been shown to be sensitive to aspects of executive functioning such as initiation and sustained effort. Here, the number of words beginning with the letters F, A and S which were recalled in 1 minute was recorded. The Stroop test consists of three subtests: words, colours and colour words that conflict with the colour in which they are presented. Here the interference score was calculated as a measure of cognitive inhibitory control [68]. The Wisconsin Card Sorting Test (WCST) is a test of executive functioning that assesses cognitive flexibility and set-shifting. The individual is asked to match pictured designs based on rules that are not presented directly but which must be inferred from feedback given about the correctness of the matches; after a series of correct matches the underlying rule is changed. Here the computerized 128-card version of the WCST was used and the number of perseverative errors was recorded [69].

Eating behaviour traits were assessed using the Three-Factor Eating Questionnaire (3FEQ) [70] and the Bulimic Investigatory Test, Edinburgh (BITE) [71]. The 3FEQ is a 51-item validated questionnaire that assesses three factors (in the form of specific subscales) that refer to cognitions and behaviours: dietary restraint, disinhibition and hunger. Dietary restraint involves the conscious control of food intake in order to control body weight. Dietary disinhibition is characterized by an overconsumption of foods in response to a variety of stimuli (e.g. emotional stress) and is associated with a loss of control over food intake. Hunger represents food intake in response to feelings and perceptions of hunger. The BITE is a 33-item, self-report questionnaire designed as an objective screening test to identify subjects with bulimic symptoms and it consists of two subscales: the symptoms scale (30 items), which determines the seriousness of the symptoms, and the severity scale (3 items), which offers a severity index. The score used in the present study was that obtained from the symptoms scale, which comprises items relating to symptoms such as bulimic behaviours and weight control strategies.

Statistical Analysis

Statistical analyses were performed by means of PASW Statistics 18.0 (SPSS Inc, Chicago, IL, USA). The Kolmogorov-Smirnov test was used to test whether all continuous variables followed a normal distribution. Frequencies of polymorphisms and alleles were calculated. Chi-square analysis tested for goodness-of-fit to the Hardy-Weinberg equilibrium. The Mann-Whitney U test was used to compare categorical variables between the genetic groups, whereas the continuous variables were compared via the Student’s t-test for independent samples. Factorial ANCOVA was performed to determine the effect of group (obesity), allele status (carrier vs. non carrier) and their interaction on executive function and eating behaviour variables controlling for confounding variables (score in HADS depression questionnaire and sex). Given the low number of participants who were simultaneously carriers of A1 (DRD2/ANKK1-TaqIA) and 7R (DRD4 VNTR), we did not examine the interaction between these two genes; instead, separate ANCOVAs were performed for each allele status (carrier vs non carrier). Finally, the effect size was calculated according to the value of eta squared (ή2). The interpretation of this statistic is as follows: ή2 = 0.0099, small effect; ή2 = 0.0588, medium effect; ή2 = 0.1379, large effect [72].


Comparisons between obese and control subjects in demographics, neuropsychological and questionnaire scores are shown in table 3.

Table 3
Comparison between obese and control subjects in demographics, neuropsychological and questionnaire scores.

Frequencies of DRD2/ANKK1-TaqIA alleles and genotypes, and the frequencies of DRD4 VNTR alleles and genotypes in obese and control subjects are shown in table 4 and table 5 respectively. As can be seen in Table 6 the frequency of allele carriers and non-carriers did not differ between obese and control participants for either of the two genotypes.

Table 4
Frequencies of DRD2/ANKK1 alleles and genotypes in obese and control subjects.
Table 5
Frequencies of DRD4 exon 3 VNTR alleles and genotypes in obese and control subjects.
Table 6
Frequencies of ‘DRD2/ANKK1-TaqIA A1-allele status’ and ‘DRD4 VNTR 7R-allele status’ in obese and control subjects.

Although age, education and estimated intelligence were equivalent for all genetic subgroups, the DRD4-7R carriers group contained significantly more females than did the group comprising non-carriers of 7R (DRD2/ANKK1-TaqIA subgroups: age: F = 0.02; p = 0.872; years of education: F = 1.15; p = 0.286; vocabulary (WAIS): F = 0.15; p = 0.693; sex: U = 584; p = 0.47; DRD4-7R subgroups: age: F = 0.02; p = 0.869; years of education: F = 0.00; p = 0.950; vocabulary (WAIS): F = 0.50; p = 0.479; sex: U = 390; p = 0.032). Therefore, to rule out the effect of sex on the DRD4 7R allele comparisons we introduced additionally this variable in the ANCOVA analysis.

Table 7 shows the effect of ‘group’, ‘DRD2/ANKK1-TaqIA A1-allele status’ and their interaction on executive functions and eating behaviour variables controlled for depression. No significant ‘group’ effects were observed for any of the executive variables. However, there was a significant main effect of ‘allele status’ on LN SDMT, TMT B, and the number of perseverative errors on the WCST. Subjects bearing the A1 allele performed worse than those non A1-carriers subjects. There was also a significant ‘group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on the LN score (Figure 1).

Table 7
Effect of ‘group’, ‘DRD2/ANKK1-TaqIA A1-allele status’ and their interactions with executive functions and eating behavior.
Figure 1
‘Group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on the LN score.

As expected, there was a significant ‘group’ effect on all the eating behaviour variables. Interestingly, however, the results also revealed a significant effect of ‘allele status’ on two of these variables (BITE symptoms and the disinhibition subscale of the 3FEQ), as well as a significant ‘group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on BITE symptoms (Figure 2).

Figure 2
‘Group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on BITE symptoms.

Table 8 shows the effect of ‘group’, ‘DRD4 VNTR 7R-allele status’ and their interaction on executive functions and eating behaviour controlled for gender and depression scores. No significant main effects of ‘group’ or ‘allele status’ were observed for any of the executive variables. However, there was a significant ‘group’ x ‘DRD4 VNTR 7R- allele status’ interaction effect on TMT B and TMT B-A scores (Figure 3). Eating behaviour variables these were all subject to a significant main effect of ‘group’.

Table 8
Effect of ‘group’, ‘DRD4 7R-allele status’ and their interactions with executive functions and eating behavior.
Figure 3
‘Group’ x ‘DRD4 VNTR 7R- allele status’ interaction effect on TMT B-A score.


The purpose of this study was to examine the association between two dopamine genes and executive function and their potential interactions with obesity. Specifically, the two dopamine system genes chosen were the DRD2/ANKK1-TaqIA and DRD4 48 bp VNTR polymorphisms. Both have been associated with psychiatric disorders involving impulsivity and obesity. In addition, these polymorphisms appear to exert a functional influence on dopamine D2 and D4 receptors, which are densely located in the corticostriatal-mesolimbic system [10][13], [73], [74], and they could potentially affect performance of frontal functions via frontosubcortical circuits linking the frontal cortex to distinct areas of the striatum [75], [76].

Previous studies have demonstrated altered executive function in obese subjects [77][79]. By contrast, we found no relationship between obesity and worse performance on executive function variables, there being no significant effect of ‘group’ on any of the executive variables analysed. Conversely, the A1 allele of the DRD2/ANKK1-TaqIA polymorphism was clearly associated with poor performance on executive tasks in both obese and control subjects. Specifically, significant differences between the two ‘allele status’ groups were observed for four of the seven executive variables analysed, with A1 allele carriers performing worse than A1 non-carriers.

Studies of frontal function and the DRD2/ANKK1-TaqIA polymorphism in healthy adult samples have yielded conflicting results. Some recent investigations have revealed carriers of the A1 allele to have better cognitive flexibility than A1 non-carriers [33], [34]. By contrast, other authors have shown that A1 carriers are less efficient at learning to avoid actions that have negative consequences [36] and that they have difficulty in learning from negative feedback in a reinforcement learning task [35]. Our A1 allele carriers (including both obese and control subjects) showed worse performance on variables involving motor speed, verbal and visuo-spatial working memory, set-shifting, attention and tracking, and cognitive flexibility. These results are therefore in line with those studies that have shown greater difficulty in performing tasks involving executive functions in subjects carrying the A1 allele, regardless of the test/task used [35], [36].

Our results also revealed a significantly ‘group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on the LN variable. In the obese group, A1 carriers performed worse than did A1 non-carriers, whereas among controls the performance of A1 carriers and non-carriers was similar. This suggests that possession of the A1 allele among obese subjects is associated with worse performance on working memory, and it could therefore confer a disadvantage in terms of executive performance. Other studies with pathological samples involving the dopaminergic system have yielded discordant results regarding frontal function. In a sample of alcoholic males those subjects bearing at least one copy of the A1 allele showed lower attention and less inhibitory control than did those without the A1 allele [80], whereas Bombin et al. [81], in a sample of psychotic adolescents, failed to detect an effect of the DRD2/ANKK1-TaqIA polymorphism on executive functions.

The A1 allele of the DRD2/ANKK1-TaqIA gene has been associated with addictive disorders [18][20]. Significant associations between the A1 allele of the DRD2/ANKK1-TaqIA polymorphism and variables that indicate pathological food intake were found in our sample. Subjects carrying the A1 allele scored higher on the BITE scale and on the disinhibition subscale of the 3FEQ, implying greater overconsumption of foods associated with a loss of control over food intake. We also found a significant interaction between ‘group’ and ‘DRD2/ANKK1-TaqIA A1-allele status’ in relation to BITE symptoms. In the obese group, carriers of the A1 allele scored significantly higher on the BITE than did A1 non-carriers. These results were expected since food reinforcement and impulsivity have been reported to be greater in obese individuals with the A1 allele [48], [82].

No significant ‘group’ or ‘DRD4 VNTR 7R-allele status’ effects were observed for any of the executive variables analysed. In this regard, our data partially support the results of previous studies that found no differences among ADHD patients in relation to the DRD4 VNTR polymorphism and cognitive functions [44], [51], [53], [56]. Interestingly, however, we did find a significant ‘group’ x ‘DRD4 VNTR 7R-allele status’ interaction effect on TMT B and TMT B-A scores. Specifically, in the obese group the performance of 7R carriers was worse than that of 7R non-carriers, whereas among controls the performance of 7R carriers was better than that of non-carriers. These results are consistent with previous studies that have reported associations between being a carrier of 7R and impairment on executive function tasks in healthy children [50], adults [54] and in children with ADHD [50][52]; they also support the findings of those authors who have reported better performance among subjects with the DRD4 long (6–8) repeats compared to the DRD4 short (2–5) repeats [53]. It would seem, therefore, that obesity is a key factor in relation to possession of the allele. Being obese and having the DRD4 7-repeat allele appears to confer a weakness in terms of the performance of executive functions.

At all events the strengths and limitations of the present study should be considered when interpreting the findings. The study sample size was modest, and research designed to identify genes that are associated with specific behaviours usually requires a much larger sample. Nevertheless, this sample size did provide enough statistical power to detect a significant interaction and main effect of gene variants on our measures of executive function, even though the effect sizes were small. The results should, however, be interpreted with caution in view of the numerous statistical comparisons, the risk being that some of the findings may be spurious. The present results therefore require confirmation by studies that are adequately powered to detect the effect of DRD2-A1 and DRD4-7R on executive performance.

Ideally one would also have investigated all possible interactions among the two polymorphisms studied here. However, for the DRD4 48-bp VNTR and the DRD2/ANKK1-TaqIA polymorphisms the genotype frequencies involving the minor allele were too low to test for meaningful interactions. Future studies should therefore address the question of all potential interactions between these two (and other) polymorphisms in dopamine system genes in a larger, adult, obese cohort.

To conclude, despite the methodological limitations, we found that obese subjects carriers of the A1 allele of the DRD2/ANKK1 TaqA1 and carriers of the 7R allele of the DRD4 48-bp VNTR polymorphism performed worse on certain tests of executive functions. These results provided new knowledge on the effect of two genes that are crucial for dopamine neurotransmission, which underlies several psychiatric disorders. The study of the genes related to dopamine transmission, with respect to both its elimination and its release or receptor binding, may shed light on the role of this system in mental disorders.

Supporting Information

Figure S1

The figure shows detailed information on data inclusion.



We acknowledge Dr Immaculada Clemente for her assistance with genetic data interpretation and Mrs Concepcio Tor who helped us to obtain blood samples.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grant 2009SGR941 from the Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya (AGAUR), by grants PSI2008-05803-C02-01/PSIC to Maria Angeles Jurado (PhD) and PSI2008-05803-C02-02/PSIC to Maite Garolera (PhD) (both from the Ministerio de Ciencia e Innovación), and by grant FI-2009 from the Generalitat de Catalunya to Isabel García-García. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Banegas JR, Lopez-Garcia E, Gutierrez-Fisac JL, Guallar-Castillon P, Rodriguez-Artalejo F. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr. 2003;57:201–208. [PubMed]
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–1245. [PubMed]
3. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003;163:1524–1528. [PubMed]
4. Gustafson D, Lissner L, Bengtsson C, Bjorkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004;63:1876–1881. [PubMed]
5. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–830. [PMC free article] [PubMed]
6. Volkow ND, O'Brien CP. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry. 2007;164:708–710. [PubMed]
7. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage. 2003;19:1709–1715. [PubMed]
8. Small DM, Bender G, Veldhuizen MG, Rudenga K, Nachtigal D, et al. The role of the human orbitofrontal cortex in taste and flavor processing. Ann N Y Acad Sci. 2007;1121:136–151. [PubMed]
9. Avena NM, Rada P, Hoebel BG. Sugar and fat bingeing have notable differences in addictive-like behavior. J Nutr. 2009;139:623–628. [PubMed]
10. Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with (3H]raclopride. Proc Natl Acad Sci U S A. 1989;86:6412–6416. [PubMed]
11. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3:256–260. [PubMed]
12. Ito H, Okubo Y, Halldin C, Farde L. Mapping of central D2 dopamine receptors in man using (11C]raclopride: PET with anatomic standardization technique. Neuroimage. 1999;9:235–242. [PubMed]
13. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4:290–296. [PubMed]
14. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23:540–545. [PubMed]
15. Ritchie T, Noble EP. 3H]naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism. Brain Res. 1996;718:193–197. [PubMed]
16. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res. 2003;28:73–82. [PubMed]
17. Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet. 1997;74:162–166. [PubMed]
18. Young RM, Lawford BR, Nutting A, Noble EP. Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav. 2004;29:1275–1294. [PubMed]
19. Munafo MR, Matheson IJ, Flint J. Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Mol Psychiatry. 2007;12:454–461. [PubMed]
20. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet. 2003;116B:103–125. [PubMed]
21. Comings DE, Flanagan SD, Dietz G, Muhleman D, Knell E, et al. The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochem Med Metab Biol. 1993;50:176–185. [PubMed]
22. Wang G, Volkow ND, Logan J, Pappas NR, Wong CT, et al. Brain dopamine and obesity. The Lancet. 2001;357:354–357. [PubMed]
23. Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, et al. D2 dopamine receptor gene and obesity. Int J Eat Disord. 1994;15:205–217. [PubMed]
24. Spitz MR, Detry MA, Pillow P, Hu Y, Amos CI, et al. Variant alleles of the D2 dopamine receptor gene and obesity. Nutr Res. 2000;20:371–380.
25. Blum K, Braverman ER, Wood RC, Gill J, Li C, et al. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics. 1996;6:297–305. [PubMed]
26. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, et al. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage. 2008;42:1537–1543. [PMC free article] [PubMed]
27. Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008;322:449–452. [PMC free article] [PubMed]
28. Volkow ND, Wang GJ, Telang F, Fowler JS, Goldstein RZ, et al. Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity. 2008;17:60–65. [PMC free article] [PubMed]
29. Willeumier KC, Taylor DV, Amen DG. Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults. Obesity (Silver Spring) 2011;19:1095–1097. [PMC free article] [PubMed]
30. Berman SM, Noble EP. Reduced visuospatial performance in children with the D2 dopamine receptor A1 allele. Behav Genet. 1995;25:45–58. [PubMed]
31. Tsai SJ, Yu YW, Lin CH, Chen TJ, Chen SP, et al. Dopamine D2 receptor and N-methyl-D-aspartate receptor 2B subunit genetic variants and intelligence. Neuropsychobiology. 2002;45:128–130. [PubMed]
32. Bartres-Faz D, Junque C, Serra-Grabulosa JM, Lopez-Alomar A, Moya A, et al. Dopamine DRD2 Taq I polymorphism associates with caudate nucleus volume and cognitive performance in memory impaired subjects. Neuroreport. 2002;13:1121–1125. [PubMed]
33. Markett S, Montag C, Walter NT, Plieger T, Reuter M. On the molecular genetics of flexibility: The case of task-switching, inhibitory control and genetic variants. Cogn Affect Behav Neurosci. 2011;11:644–651. [PubMed]
34. Stelzel C, Basten U, Montag C, Reuter M, Fiebach CJ. Frontostriatal involvement in task switching depends on genetic differences in d2 receptor density. J Neurosci. 2010;30:14205–14212. [PubMed]
35. Jocham G, Klein TA, Neumann J, von Cramon DY, Reuter M, et al. Dopamine DRD2 polymorphism alters reversal learning and associated neural activity. J Neurosci. 2009;29:3695–3704. [PMC free article] [PubMed]
36. Klein TA, Neumann J, Reuter M, Hennig J, von Cramon DY, et al. Genetically determined differences in learning from errors. Science. 2007;318:1642–1645. [PubMed]
37. Reuter M, Peters K, Schroeter K, Koebke W, Lenardon D, et al. The influence of the dopaminergic system on cognitive functioning: A molecular genetic approach. Behav Brain Res. 2005;164:93–99. [PubMed]
38. Meador-Woodruff JH, Grandy DK, Van Tol HH, Damask SP, Little KY, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology. 1994;10:239–248. [PubMed]
39. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, et al. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology. 1996;15:17–29. [PubMed]
40. Chang FM, Kidd JR, Livak KJ, Pakstis AJ, Kidd KK. The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum Genet. 1996;98:91–101. [PubMed]
41. Schoots O, Van Tol HH. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J. 2003;3:343–348. [PubMed]
42. Comings DE, Gonzalez N, Wu S, Gade R, Muhleman D, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999;88:358–368. [PubMed]
43. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, et al. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm. 2003;110:111–121. [PubMed]
44. Swanson J, Oosterlaan J, Murias M, Schuck S, Flodman P, et al. Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine receptor D4 gene have extreme behavior but normal performance on critical neuropsychological tests of attention. Proc Natl Acad Sci U S A. 2000;97:4754–4759. [PubMed]
45. Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1052–1057. [PubMed]
46. Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet. 2006;15:2276–2284. [PubMed]
47. Levitan RD, Masellis M, Basile VS, Lam RW, Kaplan AS, et al. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol Psychiatry. 2004;56:665–669. [PubMed]
48. Eisenberg DT, Mackillop J, Modi M, Beauchemin J, Dang D, et al. Examining impulsivity as an endophenotype using a behavioral approach: a DRD2 TaqI A and DRD4 48-bp VNTR association study. Behav Brain Funct. 2007;3:2. [PMC free article] [PubMed]
49. Congdon E, Lesch KP, Canli T. Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:27–32. [PubMed]
50. Froehlich TE, Lanphear BP, Dietrich KN, Cory-Slechta DA, Wang N, et al. Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children. Biol Psychiatry. 2007;62:243–249. [PubMed]
51. Langley K, Marshall L, van den Bree M, Thomas H, Owen M, et al. Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. Am J Psychiatry. 2004;161:133–138. [PubMed]
52. Waldman ID. Statistical approaches to complex phenotypes: evaluating neuropsychological endophenotypes for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1347–1356. [PubMed]
53. Manor I, Tyano S, Eisenberg J, Bachner-Melman R, Kotler M, et al. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Mol Psychiatry. 2002;7:790–794. [PubMed]
54. Szekely A, Balota DA, Duchek JM, Nemoda Z, Vereczkei A, et al. Genetic factors of reaction time performance: DRD4 7-repeat allele associated with slower responses. Genes Brain Behav. 2011;10:129–136. [PubMed]
55. Young JW, Powell SB, Scott CN, Zhou X, Geyer MA. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res. 2011;222:183–192. [PMC free article] [PubMed]
56. Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, et al. Assessing the molecular genetics of attention networks. BMC Neurosci. 2002;3:14. [PMC free article] [PubMed]
57. Braw Y, Aviram S, Bloch Y, Levkovitz Y. The effects of age on frontal lobe related cognitive functions of unmedicated depressed patients. J Affect Disord. 2011;129:342–347. [PubMed]
58. Cserjési R, Luminet O, Poncelet AS, Lénárd L. Altered executive function in obesity. Exploration of the role of affective states on cognitive abilities. Appetite. 2009;52:535–539. [PubMed]
59. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J. 2006;Psychiatry163:1594–602. [PubMed]
60. Zigmond. The Hospital Anxiety and Depression Scale. Acta psychiatrica Scandinavica. Supplementum. 1983;67:361. [PubMed]
61. First MB, Spitzer RL, Gibbon M, Williams JBW. Barcelona: Masson. 1999. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician, 1st ed.
62. Crowe SF. Does the letter number sequencing task measure anything more than digit span? Assessment. 2000;7:113–117. [PubMed]
63. Wechsler D. WAIS III. Escala de Inteligencia de Wechsler para adultos III. 1999. (adaptación española ed.).
64. Smith A. Test de Símbolos y Dígitos (SDMT): manual. Madrid: TEA Editores S.A. 2005.
65. Reitan RM. Validity of the Trail Making Test as an indicator of organix brain damage. Percept Mot Skills. 1958;8:271–276.
66. Lezak MD, Howieson DB, Loring DW. New York: Oxford University Press. 2004. Neuropsychological Assessment, 4th ed.
67. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City: AJA Associates. 1989.
68. Golden CJ. STROOP, test de colores y palabras Madrid: TEA Ediciones. 1995.
69. Heaton RK. Wisconsin Card Sorting Test: Computer Version 4-Research Edition. Psychological Assessment Resources. 1999.
70. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29:71–83. [PubMed]
71. Henderson M, Freeman CP. A self-rating scale for bulimia. The 'BITE'. Br J Psychiatry. 1987;150:18–24. [PubMed]
72. Cohen J. New York: Academic Press. 1988. Statistical power analysis for the behavioural sciences, 2a ed.
73. Oak JN, Oldenhof J, Van Tol HH. The dopamine D(4) receptor: one decade of research. Eur J Pharmacol. 2000;405:303–327. [PubMed]
74. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, et al. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry. 1997;54:1089–1095. [PubMed]
75. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–381. [PubMed]
76. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50:873–880. [PubMed]
77. Boeka AG, Lokke KL. Neuropsychological performance of a clinical sample of extremely obese individuals. Arch Clin Neuropsychol. 2008;23:467–474. [PubMed]
78. Lokken KL, Boeka AG, Yellumahanthi K, Wesley M, Clements RH. Cognitive performance of morbidly obese patients seeking bariatric surgery. Am Surg. 2010;76:55–59. [PubMed]
79. Gunstad J, Paul R, Cohen R, Tate D, Spitznagel M, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48:57–61. [PubMed]
80. Rodriguez-Jimenez R, Avila C, Ponce G, Ibanez MI, Rubio G, et al. The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patients. Eur Psychiatry. 2006;21:66–69. [PubMed]
81. Bombin I, Arango C, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, et al. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:873–879. [PubMed]
82. Epstein LH, Temple JL, Neaderhiser BJ, Salis RJ, Erbe RW, et al. Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans. Behav Neurosci. 2007;121:877–886. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science